Breaking News

Pfizer Completes $43B Seagen Acquisition

Full-Year 2024 guidance has cost realignment program involving undisclosed layoffs now expected to deliver annual cost savings of at least $4.0 billion.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer completed its approximately $43 billion acquisition of Seagen Inc., a global biotechnology that develops and commercializes cancer medicines leveraging ADC technology designed to preferentially kill cancer cells and limit off-target toxicities.    With the addition of Seagen’s four in-line medicines, ADCETRIS (brentuximab vedotin), PADCEV (enfortumab vedotin), TIVDAK (tisotumab vedotin) and TUKYSA (tucatinib), Pfizer’s oncology portfolio now includes over 25 approved medicines and biosi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters